Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

A recent study found that vaginal rings and even skin patches had used the same combination of hormones that pose similar ...

The use of combined oral contraceptives may delay the onset of hidradenitis suppurativa among women and may improve disease severity.

The study revealed the risk of developing venous thromboembolisms from various types of synthetic hormones, providing ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Polycystic ovary syndrome (PCOS) is a common hormonal disorder that affects millions of women worldwide. One of the most ...